Park Avenue Securities LLC Raises Stake in Repligen Co. (NASDAQ:RGEN)

Park Avenue Securities LLC lifted its position in Repligen Co. (NASDAQ:RGEN) by 24.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,901 shares of the biotechnology company’s stock after purchasing an additional 776 shares during the period. Park Avenue Securities LLC’s holdings in Repligen were worth $561,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Envestnet Asset Management Inc. increased its stake in Repligen by 0.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 108,741 shares of the biotechnology company’s stock worth $13,708,000 after buying an additional 741 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Repligen by 39.4% in the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after acquiring an additional 121,305 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Repligen during the second quarter worth about $5,320,000. Vanguard Personalized Indexing Management LLC raised its stake in Repligen by 3.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 5,125 shares of the biotechnology company’s stock valued at $646,000 after purchasing an additional 184 shares during the period. Finally, Hsbc Holdings PLC lifted its holdings in Repligen by 14.5% in the 2nd quarter. Hsbc Holdings PLC now owns 14,178 shares of the biotechnology company’s stock worth $1,785,000 after purchasing an additional 1,791 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on RGEN shares. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $185.20.

Repligen Stock Performance

NASDAQ RGEN opened at $166.84 on Thursday. The company has a market cap of $9.35 billion, a P/E ratio of -450.91, a P/E/G ratio of 4.29 and a beta of 0.97. The business’s 50 day moving average price is $149.17 and its 200-day moving average price is $145.43. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the prior year, the firm posted $0.23 earnings per share. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. Sell-side analysts predict that Repligen Co. will post 1.54 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.